Immunovant, Inc.
Clinical-stage immunology company developing anti-FcRn antibodies for autoimmune diseases.
IMVT | US
Overview
Corporate Details
- ISIN(s):
- US45258J1025
- LEI:
- Country:
- United States of America
- Address:
- 320 WEST 37TH STREET, 10018 NEW YORK
- Website:
- https://immunovant.com/
Description
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The company develops monoclonal antibodies designed to treat a range of autoimmune conditions. Its therapeutic approach focuses on targeting the neonatal Fc receptor (FcRn) to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which are central drivers of many autoimmune diseases. The company's pipeline is centered on developing anti-FcRn antibodies, including its product candidate IMVT-1402, for subcutaneous administration.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immunovant, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunovant, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunovant, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
